Understanding the dispersibility enhancement of L-leucine in the spray drying of inhalable microparticles

Mani Ordoubadi¹, Hui Wang¹, Mark Nicholas², Sandra Gracin², David Lechuga-Ballesteros³, Warren H. Finlay¹, Reinhard Vehring¹

¹Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada

²Inhalation Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden

³Inhalation Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, South San Francisco, California, USA







Introduction

- Dispersibility enhancers are used during spray drying to decrease interparticle cohesion and adhesion with the device components.
- L-leucine is one of the dispersibility enhancers currently in clinical development¹.
- It is surface-active and crystallizes during spray drying².
- The underlying mechanisms of shell formation of leucine during spray drying is not understood fully.
- These facts complicate the use of conventional particle formation theories in predicting the surface enrichment of leucine-containing particles and their solid phase.



Methods – Drying of Leucine and Trehalose Particles



Lab-Scale Spray Dryer (B-191)

 $T_{\rm in} = 75 \,^{\circ}{\rm C}$ $d_0 \cong 8 \,\mu{
m m}$

- SEM
- ToF-SIMS
- Raman spectroscopy





The 10 μ m scale bar corresponds to all figures but the insets for which separate scale bars are provided.

Spray-Dried Powders – Smaller Particles Have Less Leucine on the Surface



Model – The Particle Formation Model Can Predict the Size-Dependency



Larger $t_{c,treh} - t_{n,leu} \rightarrow more$ leucine on the surface, higher leucine crystallinity Smaller $t_{c,treh} - t_{n,leu} \rightarrow less$ leucine on the surface, lower leucine crystallinity

- <u>Leucine</u> is expected to undergo instantaneous nucleation upon reaching a supersaturation ratio of $\sim 3.5^3$.
- <u>Trehalose</u> is expected to begin its glass formation process upon reaching a concentration of ~830 mg/mL².

Conclusions

- Leucine acts as a dispersibility enhancer mostly by making a rugose crystalline shell on the particle surface*.
- Leucine-containing particles cannot be designed according to a simple formulation composition rule.
- Not given enough time for crystallization, some of the leucine molecules in the particles would make a co-amorphous mixture with the other glass formers.
- This can be predicted with the proposed particle formation model.



7

* Low quantities of leucine in amorphous phase can still lower the surface energy, hence increase the dispersibility, of particles due to its surface-activity (not studied here).

References

¹ D. Lechuga-Ballesteros, S. Hoe, and B. W. Maynor, "Particle Engineering Technology for Inhaled Therapies," in *Pharmaceutical Inhalation Aerosol Technology*, 3rd ed., A. J. Hickey and S. R. P. da Rocha, Eds. Boca Raton, Florida: CRC Press, 2019, pp. 349–361.

² M. Ordoubadi, F.K.A. Gregson, H. Wang, M. Nicholas, S. Gracin, D. Lechuga-Ballesteros, J.P. Reid, W.H. Finlay, R. Vehring, On the particle formation of leucine in spray drying of inhalable microparticles, Int. J. Pharm. 592 (2021) 120102.

³ G. He, V. Bhamidi, R.B.H. Tan, P.J.A. Kenis, C.F. Zukoski, Determination of Critical Supersaturation from Microdroplet Evaporation Experiments, Cryst. Growth Des. 6 (2006)

⁴ R. Vehring, Pharmaceutical Particle Engineering via Spray Drying, Pharm. Res. 25 (2008) 999–1022.

Thank you!

